Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“The unique features of tumor angiogenesis and lymphangiogenesis contribute to accumulation of systemically administered macromolecular compounds, a phenomenon better known as enhanced permeability and retention effect (EPR; Figure 1) [Maeda, 2001].”
BackgroundXia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933 · cited 1×
“Their large surface allows delivery of drugs in larger amounts [Xia et al. 2009].”
BackgroundBrahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765 · cited 1×
“In this regard, besides their numerous mechanisms to overcome treatment effects, tumors grow to be viable in hypoxic conditions and less dependent on their vascular beds as part of their evolution process [Brahimi-Horn et al. 2007].”
Background
Cited by
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Zhang, K., Xu, H., Jia, X., Chen, Y., Ma, M., Sun, L., & Chen, H. (2016) · ACS Nano · doi:10.1021/acsnano.6b04921 · Cited by 265
Recent advances in drug delivery systems for targeting cancer stem cells
Duan, H., Liu, Y., Gao, Z., & Huang, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.016 · Cited by 256
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Lai, B. F. L., Lu, R. X. Z., Hu, Y., Davenport Huyer, L., Dou, W., Wang, E. Y., Radulovich, N., Tsao, M. S., Sun, Y., & Radisic, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202000545 · Cited by 142
Metadata
- Authors
- Dimou, A., Syrigos, K. N., & Saif, M. W.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2012-04-30
- Volume
- 4
- Issue
- 5
- Pages
- 271-279
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2049432837
- Cited by
- 65
- References
- 5
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. https://app.cochat.ai/papers/10.1177/1758834012446008
- The paper
- Dimou, A., Syrigos, K. N., & Saif, M. W. (2012). Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758834012446008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.